MicroRNA‑124‑3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study

He,Rong‑Quan; Yang,Xia; Liang,Liang; Chen,Gang; Ma,Jie

doi:10.3892/ol.2018.8045

MicroRNA‑124‑3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study

Authors:
- Rong‑Quan He
- Xia Yang
- Liang Liang
- Gang Chen
- Jie Ma
View Affiliations

Affiliations: Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of General Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: February 13, 2018 https://doi.org/10.3892/ol.2018.8045
Pages: 5517-5532
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the potential clinical significance of microRNA (miR)-124-3p expression in the hepatocarcinogenesis and development of hepatocellular carcinoma (HCC), as well as the potential target genes of functional HCC pathways. Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate the expression of miR‑124‑3p in 101 HCC and adjacent non‑cancerous tissue samples. Additionally, the association between miR‑124‑3p expression and clinical parameters was also analyzed. Differentially expressed genes identified following miR‑124‑3p transfection, the prospective target genes predicted in silico and the key genes of HCC obtained from Natural Language Processing (NLP) were integrated to obtain potential target genes of miR‑124‑3p in HCC. Relevant signaling pathways were assessed with protein‑protein interaction (PPI) networks, Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Protein Annotation Through Evolutionary Relationships (PANTHER) pathway enrichment analysis. miR‑124‑3p expression was significantly reduced in HCC tissues compared with expression in adjacent non‑cancerous liver tissues. In HCC, miR‑124‑3p was demonstrated to be associated with clinical stage. The mean survival time of the low miR‑124‑3p expression group was reduced compared with that of the high expression group. A total of 132 genes overlapped from differentially expressed genes, miR‑124‑3p predicted target genes and NLP identified genes. PPI network construction revealed a total of 109 nodes and 386 edges, and 20 key genes were identified. The major enriched terms of three GO categories included regulation of cell proliferation, positive regulation of cellular biosynthetic processes, cell leading edge, cytosol and cell projection, protein kinase activity, transcription activator activity and enzyme binding. KEGG analysis revealed pancreatic cancer, prostate cancer and non‑small cell lung cancer as the top three terms. Angiogenesis, the endothelial growth factor receptor signaling pathway and the fibroblast growth factor signaling pathway were identified as the most significant terms in the PANTHER pathway analysis. The present study confirmed that miR‑124‑3p acts as a tumor suppressor in HCC. miR‑124‑3p may target multiple genes, exerting its effect spatiotemporally, or in combination with a diverse range of processes in HCC. Functional characterization of miR‑124‑3p targets will offer novel insight into the molecular changes that occur in HCC progression.

View Figures

View References

1	Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC and Jiang N: MiR-501-5p regulates CYLD expression and promotes cell proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol. 45:738–744. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lu Y, Yue X, Cui Y, Zhang J and Wang K: MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun. 441:873–879. 2013. View Article : Google Scholar : PubMed/NCBI
3	Otsuka M, Kishikawa T, Yoshikawa T, Yamagami M, Ohno M, Takata A, Shibata C, Ishibashi R and Koike K: MicroRNAs and liver disease. J Hum Genet. 62:75–80. 2017. View Article : Google Scholar : PubMed/NCBI
4	Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM and Zhang GZ: Biological functions of microRNAs: A review. J Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
5	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bosch FX, Ribes J, Diaz M and Cleries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
7	Sherman M: Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin Liver Dis. 30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shangguan H, Tan SY and Zhang JR: Bioinformatics analysis of gene expression profiles in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 19:2054–2061. 2015.PubMed/NCBI
9	Huang S and He X: The role of microRNAs in liver cancer progression. Br J Cancer. 104:235–240. 2011. View Article : Google Scholar : PubMed/NCBI
10	Lang Q and Ling C: MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun. 426:247–252. 2012. View Article : Google Scholar : PubMed/NCBI
11	Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
12	World Health Organization (WHO), . WHO Handbook for Reporting Results of Cancer Treatment. WHO; Geneva: 1979
13	Rong M, He R, Dang Y and Chen G: Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci. 119:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
14	Rong M, Chen G and Dang Y: Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 13:212013. View Article : Google Scholar : PubMed/NCBI
15	Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J: miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 8:e603172013. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Ren F, Luo Y, Rong M, Chen G and Dang Y: Down-regulation of miR-193a-3p dictates deterioration of HCC: A clinical real-time qRT-PCR study. Med Sci Monit. 21:2352–2360. 2015. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Egger M, Smith GD and Altman DG: Systematic Reviews in Health Care. Meta-analysis in Context. 2nd. BMJ Publishing Group; London: 2001, View Article : Google Scholar
19	Murakami Y, Kubo S, Tamori A, Itami S, Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH: Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci Rep. 5:162942015. View Article : Google Scholar : PubMed/NCBI
20	Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, Zamboni F and Farci P: Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer. 133:816–824. 2013. View Article : Google Scholar : PubMed/NCBI
21	Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and Shimizu K: MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria. PLoS One. 6:e164352011. View Article : Google Scholar : PubMed/NCBI
22	He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
23	Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wang PR, Xu M, Toffanin S, Li Y, Llovet JM and Russell DW: Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci USA. 109:pp. 11264–11269. 2012; View Article : Google Scholar : PubMed/NCBI
25	Wang X and Wang X: Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res. 34:1646–1652. 2006. View Article : Google Scholar : PubMed/NCBI
26	Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods. 12:6972015. View Article : Google Scholar : PubMed/NCBI
27	Chang EK, Yu CY, Clarke R, Hackbarth A, Sanders T, Esrailian E, Hommes DW and Runyon BA: Defining a patient population with cirrhosis: An automated algorithm with natural language processing. J Clin Gastroenterol. 50:889–894. 2016. View Article : Google Scholar : PubMed/NCBI
28	Alsawas M, Alahdab F, Asi N, Li DC, Wang Z and Murad MH: Natural language processing: Use in EBM and a guide for appraisal. Evid Based Med. 21:136–138. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhang X, Tang W, Chen G, Ren F, Liang H, Dang Y and Rong M: An encapsulation of gene signatures for hepatocellular carcinoma, microRNA-132 predicted target genes and the corresponding overlaps. PLoS One. 11:e01594982016. View Article : Google Scholar : PubMed/NCBI
30	Huang WT, Wang HL, Yang H, Ren FH, Luo YH, Huang CQ, Liang YY, Liang HW, Chen G and Dang YW: Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: A clinicopathological and in silico study. Onco Targets Ther. 9:5163–5180. 2016. View Article : Google Scholar : PubMed/NCBI
31	Liese J, Peveling-Oberhag J, Doering C, Schnitzbauer AA, Herrmann E, Zangos S, Hansmann ML, Moench C, Welker MW, Zeuzem S, et al: A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int. 29:369–380. 2016. View Article : Google Scholar : PubMed/NCBI
32	Ito K and Murphy D: Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol. 2:e792013. View Article : Google Scholar : PubMed/NCBI
33	Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang Z, Wu C, Jin T, Pan A, Wei R, et al: miRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther. 12:207–219. 2013. View Article : Google Scholar : PubMed/NCBI
34	Ma Y, Han W, Yang L, He L and Wang H: The regulation of miRNAs in inflammation-related carcinogenesis. Curr Pharm Des. 21:3023–3031. 2015. View Article : Google Scholar : PubMed/NCBI
35	Wan X, Ding X, Chen S, Song H, Jiang H, Fang Y, Li P and Guo J: The functional sites of miRNAs and lncRNAs in gastric carcinogenesis. Tumour Biol. 36:521–532. 2015. View Article : Google Scholar : PubMed/NCBI
36	Xu L, Dai W, Li J, He LI, Wang F, Xia Y, Chen K, Li S, Liu T, Lu J, et al: Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3. Oncotarget. 7:26027–26041. 2016.PubMed/NCBI
37	Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289. 2012. View Article : Google Scholar : PubMed/NCBI
38	Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ and deVere White RW: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 32:4130–4138. 2013. View Article : Google Scholar : PubMed/NCBI
39	Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T, Song E and Yu F: miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer. 30:821–830. 2011. View Article : Google Scholar : PubMed/NCBI
40	Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D and Zhou Y: The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 45:197–208. 2014. View Article : Google Scholar : PubMed/NCBI
41	Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 33:514–524. 2014. View Article : Google Scholar : PubMed/NCBI
42	Zhao W, Cheng Y, Zhang C, You Q, Shen X, Guo W and Jiao Y: Genome-wide identification and characterization of circular RNAs by high throughput sequencing in soybean. Sci Rep. 7:56362017. View Article : Google Scholar : PubMed/NCBI
43	Becker HF, Heliou A, Djaout K, Lestini R, Regnier M and Myllykallio H: High-throughput sequencing reveals circular substrates for an archaeal RNA ligase. RNA Biology. 14:1075–1085. 2017. View Article : Google Scholar : PubMed/NCBI
44	Nair AA, Niu N, Tang X, Thompson KJ, Wang L, Kocher JP, Subramanian S and Kalari KR: Circular RNAs and their associations with breast cancer subtypes. Oncotarget. 7:80967–80979. 2016. View Article : Google Scholar : PubMed/NCBI
45	Wang X, Zhang Y, Huang L, Zhang J, Pan F, Li B, Yan Y, Jia B, Liu H, Li S and Zheng W: Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances. Int J Clin Exp Pathol. 8:16020–16025. 2015.PubMed/NCBI
46	Li P, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B and Guo J: Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 444:132–136. 2015. View Article : Google Scholar : PubMed/NCBI
47	Shang X, Li G, Liu H, Li T, Liu J, Zhao Q and Wang C: Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular RNA biomarker, is involved in hepatocellular crcinoma development. Medicine (Baltimore). 95:e38112016. View Article : Google Scholar : PubMed/NCBI
48	Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, Yang J, Fan J, Liu L and Qin W: Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark. 16:161–169. 2016. View Article : Google Scholar : PubMed/NCBI
49	Xu L, Zhang M, Zheng X, Yi P, Lan C and Xu M: The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 143:17–27. 2017. View Article : Google Scholar : PubMed/NCBI
50	Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, Luo Y, Lyu D, Li Y, Shi G, et al: Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 7:112152016. View Article : Google Scholar : PubMed/NCBI
51	Gong XL and Qin SK: Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 22:6582–6594. 2016. View Article : Google Scholar : PubMed/NCBI